The Role for Consolidative Local Therapy in Stage IV Non-Small Cell Lung Cancer for Oligometastases and Beyond: How are We Improving Outcomes for Patients?

The Role for Consolidative Local Therapy in Stage IV Non-Small Cell Lung Cancer for Oligometastases and Beyond: How are We Improving Outcomes for Patients? is organized by American Society for Radiation Oncology (ASTRO).

Course opens: 07/09/2024
Course expires: 07/08/2026

Description:
Patients with Stage IV Lung cancer vary in their response to the numerous systemic therapies and are living longer. The role of aggressive local therapy or metastatic directed therapy (MDT) is critical for radiation oncologists and surgeons. It is important for clinicians to recognize that patients with limited metastatic burden could potentially derive progressive disease and survival benefits from MDT. The aim is to present difficult cases for patients with Stage IV Lung cancer to discuss evidence for the clinical benefit of aggressive local therapy with radiation or surgery. These patients will include those with oligometastases and oligoprogression of lung cancer. The speakers discuss technological advances in MDT, which patients may derive benefit from local therapy, and treatment recommendations. The speakers also discuss the need for multidisciplinary care with systemic therapy and local therapy for optimal management for patients with metastatic lung cancer.  

Topic:

• Introductions
• The Role for Surgery in Stage IV NSCLC: Moving the Needle for Operable Disease and Difficult Cases
• Consolidative Radiation Therapy Beyond Oligometastases in Stage IV NSCLC, Treatment Approaches with More Curative Intent and Difficult Cases 
• Stage IV Non-Small Cell Lung Cancer - Which Patients with Actionable Mutations Survive Longer and Should be Approached and Treated with More Curative Intent?

Learning Objectives:
Upon completion of this activity, participants should be able to:

• Allow attendees the opportunity to learn about the latest clinical research.
• Learn the guidelines on treating Stage IV Lung cancer, and understand the wide spectrum of patients who benefit from a multidisciplinary approach. 
• Know which patients can benefit from aggressive local therapy and understand the advanced technology used to improve patient outcomes.